Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism | Clinical Epigenetics | Full Text https://t.co/0UjB0cxbmZ
RT @SomaLogic: How is a drug reducing the risk of a #heartattack? Proteins in the blood may offer a clue. #hearthealth #heart #Heartawarene…
RT @SomaLogic: How is a drug reducing the risk of a #heartattack? Proteins in the blood may offer a clue. #hearthealth #heart #Heartawarene…
How is a drug reducing the risk of a #heartattack? Proteins in the blood may offer a clue. #hearthealth #heart #Heartawarenessmonth #cardiotwitter #medtwitter #health #medtech #healthtech https://t.co/s9eaTt4AkC
RT @SomaLogic: How are #drugs actually treating #disease at the molecular level? #proteins are helping to answer that question. #clinicaltr…
RT @SomaLogic: How are #drugs actually treating #disease at the molecular level? #proteins are helping to answer that question. #clinicaltr…
How are #drugs actually treating #disease at the molecular level? #proteins are helping to answer that question. #clinicaltrial #healthtech #medtech #biomed #biotech #heatlthcare #pharma https://t.co/PebIl5TjLB
RT @kamkalantar: Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism h…
Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism https://t.co/YUA0HR8Eij
RT @kamkalantar: Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism h…
Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism https://t.co/t1qNCf6NO9